Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres

Susanna Ranta, Jayashree Motwani, Jan Blatny, Martina Bührlen, Manuel Carcao, Hervé Chambost, Carmen Escuriola, Kathelijn Fischer, Mutlu Kartal-Kaess, Marloes de Kovel, Gili Kenet, Christoph Male, Beatrice Nolan, Roseline d'Oiron, Martin Olivieri, Ester Zapotocka, Nadine G Andersson, Christoph Königs, Susanna Ranta, Jayashree Motwani, Jan Blatny, Martina Bührlen, Manuel Carcao, Hervé Chambost, Carmen Escuriola, Kathelijn Fischer, Mutlu Kartal-Kaess, Marloes de Kovel, Gili Kenet, Christoph Male, Beatrice Nolan, Roseline d'Oiron, Martin Olivieri, Ester Zapotocka, Nadine G Andersson, Christoph Königs

Abstract

Introduction: Haemophilia A care has changed with the introduction of emicizumab. Experience on the youngest children is still scarce and clinical practice varies between haemophilia treatment centres.

Aim: We aimed to assess the current clinical practice on emicizumab prophylaxis within PedNet, a collaborative research platform for paediatricians treating children with haemophilia.

Methods: An electronic survey was sent to all PedNet members (n = 32) between October 2022 and February 2023. The survey included questions on the availability of emicizumab, on the practice of initiating prophylaxis in previously untreated or minimally treated patients (PUPs or MTPs) and emicizumab use in patients with or without inhibitors.

Results: All but four centres (28/32; 88%) responded. Emicizumab was available in clinical practice in 25/28 centres (89%), and in 3/28 for selected patients only (e.g. with inhibitors). Emicizumab was the preferred choice for prophylaxis in PUPs or MTPs in 20/25 centres; most (85%) started emicizumab prophylaxis before 1 year of age (30% before 6 months of age) and without concomitant FVIII (16/20; 80%). After the loading dose, 13/28 centres administered the recommended dosing, while the others adjusted the interval of injections to give whole vials. In inhibitor patients, the use of emicizumab during ITI was common, with low-dose ITI being the preferred protocol.

Conclusion: Most centres choose to initiate prophylaxis with emicizumab before 12 months of age and without concomitant FVIII. In inhibitor patients, ITI is mostly given in addition to emicizumab, but there was no common practice on how to proceed after successful ITI.

Keywords: ITI; PUPs; children; emicizumab; inhibitors; survey.

© 2023 The Authors. Haemophilia published by John Wiley & Sons Ltd.

References

REFERENCES

    1. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-1574. doi:10.1038/nm.2942
    1. Oldenburg J, Levy GG. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(22):2194-2195. doi:10.1056/NEJMc1712683
    1. Mason JA, Young G. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: illustrative real-world cases to support shared decision-making. Haemophilia. 2021;27(5):724-729. doi:10.1111/hae.14353
    1. Pipe SWCP, Dhalluin S, Kenet G, et al. Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: results from the Interim Analysis of the HAVEN 7 Study. Blood. 2022;140(S1):457-459. doi:10.1182/blood-2022-157264
    1. Andersson NG, Auerswald G, Barnes C, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B-the impact of prophylactic treatment. Br J Haematol. 2017;179(2):298-307. doi:10.1111/bjh.14844
    1. Andersson NG, Chalmers EA, Kenet G, et al. Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica. 2019;104(10):2100-2106. doi:10.3324/haematol.2018.209619
    1. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055. doi:10.1182/blood-2012-09-457036
    1. Fischer K, Ljung R, Platokouki H, et al. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia. 2014;20(4):e280-e286. doi:10.1111/hae.12448
    1. Saultier P, Guillaume Y, Demiguel V, et al. Compliance with early long-term prophylaxis guidelines for severe hemophilia A. J Pediatr. 2021;234:212-219 e3. doi:10.1016/j.jpeds.2021.02.071
    1. Nijdam A, Altisent C, Carcao MD, et al. Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica. 2015;100(3):e84-e86. doi:10.3324/haematol.2014.115709
    1. Ljung R, de Kovel M, van den Berg HM, PedNet study group. Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts. Haemophilia. 2023;29(2):498-504. doi:10.1111/hae.14729
    1. Samuelson BannowB, Recht M, Negrier C, et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 2019;35:43-50. doi:10.1016/j.blre.2019.03.002
    1. Bansal S, Donners AAMT, Fischer K, et al. Low dose emicizumab prophylaxis in haemophilia a patients: a pilot study from India. Haemophilia. 2023;29:931-934.
    1. Yu JK, Iorio A, Chelle P, Edginton AN. Pharmacokinetic implications of dosing emicizumab based on vial size: a simulation study. Haemophilia. 2021;27(3):358-365. doi:10.1111/hae.14292
    1. Donners AAMT, van der Zwet K, Rademaker CMA, Egberts TCG, Schutgens REG, Fischer K. The efficacy of the entire-vial dosing of emicizumab: real-world evidence on plasma concentrations, bleeds, and drug waste. Res Pract Thromb Haemost. 2023;7:100074. doi:10.1016/j.rpth.2023.100074
    1. Donners AAMT, Rademaker CMA, Bevers LAH, et al. Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review. Clin Pharmacokinet. 2021;60:1395-1406. doi:10.1007/s40262-021-01042-w
    1. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676-684. doi:10.1111/hae.13762
    1. Carcao M, Mancuso ME, Young G, Jimenez-Yuste V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021;14(2):143-148. doi:10.1080/17474086.2021.1875817

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit